Bioavailability of Ubiquinol in Huntington Disease

Completed · Phase 1

Conditions studied: Huntington Disease

In brief

The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals. Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.

Key facts

Study ID

NCT00980694

Run by

University of Rochester

People needed

6

Starts

2009-09-01

Expected to finish

2012-07-01

Last updated by the study team

2016-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have manifest Huntington disease
• Be 18 years of age or older
• Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
• Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit

You may not qualify if…

• Have a history of intolerability of sensitivity to CoQ
• Have an unstable medical or psychiatric illness
• Be pregnant or breastfeeding; women of childbearing age must use reliable contraception

Where it is running

• University of Rochester — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.